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Abstract 
Review on mesothelioma, with data on clinics, and 
the genes involved. 
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Identity 
Phylum 
Lung, Heart, Skin, Other: Lung: Pleura: Malignant 
Mesothelioma 
Note 
Malignant mesothelioma is a rare, aggressive cancer 
usually associated with exposure to asbestos.  Most 
(~80%) mesotheliomas originate from mesothelial 
cells lining the pleural cavity and are referred to as 
malignant pleural mesotheliomas (MPM); the 
remainder arise from mesothelial cells that line the 
peritoneum (15-20%), pericardium (1%), or tunica 
vaginalis (<1%) (Tischoff et al., 2011).  MPM is 
characterized by a long latency, typically 20-40 
years, from the time of asbestos exposure to 
diagnosis, suggesting that multiple somatic 
genetic/epigenetic events are required for 
tumorigenic conversion of a mesothelial cell 
(Murthy and Testa, 1999). 
Clinics and pathology 
Etiology 
Asbestos is the major causative factor in the 
pathogenesis of MPM.  Approximately 80% of 
MPM patients report histories of exposure 
(Prazakova et al., 2014), but it is unknown how 
asbestos exposure leads to cellular transformation of 
normal mesothelial cells.  The remaining 20% of 
MPM cases without a recognized history of exposure 
to asbestos may be related to alternative factors, 
including radiation or thorotrast exposure (Carbone 
et al., 2002).  Genetic predisposition can also play a 
prominent role in familial cases (Testa et al., 2011). 
Chronic inflammation related to exposure to 
asbestos fibers is thought to contribute to the 
etiology of MPM (Hillegass et al., 2010; Matsuzaki 
et al., 2012).  Asbestos can be found in human lungs 
after many years, and asbestos fiber concentrations 
in lung tissues may not diminish significantly over 
time after exposure cessation (Feder et al., 2017). 
Recently, high mobility group box protein-1 ( 
HMGB1), a non-histone chromatin-binding protein 
that regulates nucleosome assembly and chromatin 
structure, has been proposed as one of the factors 
responsible for the initiation and perpetuation of the 
inflammatory response in MPM (Carbone and Yang, 
2012). 
Clinics 
Approximately 3,200 new cases of mesothelioma are 
diagnosed in United States annually, and the 
incidence worldwide is expected to rise over the next 
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two decades (Henley et al, 2013).  MPM has a very 
poor prognosis, with the median survival being less 
than 12 months (Mineo and Ambrogi, 2012). 
Pathology 
The World Health Organization Classification of 
Tumors of the Pleura has recently updated the 
classification of MPM (Galateau-Salle et al., 2016).  
MPM is classified into 3 major histological subtypes 
accordingly to the morphology of the cells: 
epithelioid (≥90% epithelial-shaped cells), 
sarcomatoid (≥90% spindle-shaped cells), and 
biphasic (consisting of significant numbers of both 
epithelial-shaped and spindle-shaped cells).  
Although the histological classification remains the 
same, some distinctions have been made related to 
prognosis.  For example, diffuse malignant 
mesothelioma (DMM) has been separated from other 
mesotheliomas, with a much better prognosis 
observed in localized malignant mesotheliomas 
(LMMs) and well-differentiated papillary 
mesotheliomas (WDPMs) (Galateau-Salle et al., 
2016). 
Cytogenetics 
Karyotypic studies and chromosome microarray 
analyses of MPM have shown that all chromosomes 
contribute to numerical and structural changes, with 
chromosomal losses being more common than gains.  
Several sites of chromosomal losses occur more 
frequently, e.g., monosomy of chromosome 22, 
which occurs in 60-70% of MPMs (Cheng et al., 
1999; De Rienzo et al., 2016).  Chromosome 
microarray and loss of heterozygosity (LOH) 
analyses have revealed frequent losses of specific 
sites in 1p, 3p, 4, 6q, 9p, 11q, 13q, 14q, 15q, 17p, 
18q, and 22q in MPM specimens and tumor-derived 
cell lines (De Rienzo et al., 2000, 2001; Lindholm et 
al., 2007; Ivanov et al., 2009; Cheung et al., 2010), 
suggesting that tumor suppressor genes may reside 
in the deleted regions.  In fact, subsequent mutation 
screening studies uncovered frequent mutations 
and/or homozygous deletions of specific tumor 
suppressor genes at several of these recurrent sites of 
chromosomal loss (see below).  Although less 
common, recurrent chromosomal gains of 5p, 7p, 8q, 
12p, 17q and 18q have also been documented in 
some studies.  Notably, losses of 1p, 3p, 6q, 9p, and 
22q often occur in combination, suggesting a 
multistep cascade involving the inactivation of 
multiple tumor suppressor genes critical in MPM 
pathogenesis (Murthy and Testa, 1999).  Data on 
malignant peritoneal mesotheliomas are fewer than 
for MPM, but two recent DNA copy number studies 
have revealed that the genomic pattern in peritoneal 
tumors is similar to that described for MPM, 
including recurrent losses of chromosomal regions 
3p21, 9p21, and 22q12, although differences were 
also observed.  For example, in one report of 
peritoneal mesotheliomas, novel genomic copy 
number alterations included loss of 8p11.2 and gain 
of 15q26.2 (Chirac et al., 2016).  In another report, 
Borczuk et al. (2016) compared DNA array-based 
findings from 48 epithelioid peritoneal 
mesotheliomas and 41 epithelioid MPMs to identify 
similarities and differences in copy number 
alterations.  Losses in 3p, 9p and 22q were seen in 
tumors from both sites, although 9p and 22q losses 
were seen at a higher rate in the pleural tumors 
(p<0.01).  Moreover, regions of copy number gain 
were more common in peritoneal tumors, whereas 
losses were more common in MPM, with regions of 
loss containing known tumor suppressor genes and 
regions of gain encompassing genes encoding 
receptor tyrosine kinase pathway members.  
Deletions in 6q, 14q, 17p and 22q, and gain of 17q 
were seen in asbestos-associated peritoneal 
mesothelioma cases, but not in peritoneal tumors 
thought to be causally related to prior radiation 
exposure.  The patterns of genomic imbalances 
suggest overlapping and distinct molecular pathways 
in mesothelioma of the pleura and peritoneum, and 
that differences in causation (i.e., asbestos vs. 
radiation) may account for some of these site-
dependent genomic differences observed. 
Treatment 
Patients receiving first line combination 
chemotherapy with cisplatin and pemetrexed have a 
median survival of about 12 months (Vogelzang et 
al., 2003).  Some patients with early MPM who 
undergo multimodality therapy that includes surgical 
resection and chemotherapy may benefit 
significantly, with longer-term survival at 5 years 
seen in up to 20% of cases (Richards, 2009). 
Genes involved and 
proteins 
Work performed in the 1990s implicated tumor 
suppressor loci at two of the recurrent sites of 
chromosomal loss first identified cytogenetically 
and/or by deletion mapping.  One of these loci, 
CDKN2A (Cheng et al., 1994), is located at 9p21.3, 
and the second, NF2 (Bianchi et al, 1995; Sekido et 
al., 1995), resides at 22q12.  The identity of the 
critical 3p21 gene in mesothelioma remained a 
mystery until 2011, however, when somatic point 
mutations of BAP1, located at 3p21.3, were 
identified in 20-25% of sporadic MPMs (Bott et al., 
2011; Testa et al., 2011).  In 2012, a Japanese group 
reported frequent biallelic alterations of BAP1, 
including homozygous deletions of part or all of this 
tumor suppressor gene as well as sequence-level 
mutations, in 61% of sporadic mesotheliomas 
(Yoshikawa et al., 2012).  Subsequent studies with 
newer next generation and multiplex ligation-
dependent probe amplification platforms confirmed 
a similarly high incidence of BAP1 alterations in this 
disease (Lo Iacono et al., 2015; Nasu et al., 2015).  
Importantly, germline mutations of BAP1 have also 
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been found in families with a high incidence of 
mesothelioma and other cancers, and the existence 
of a germline BAP1 mutation may predispose to the 
carcinogenic effects of asbestos (Testa et al., 2011). 
BAP1 
Location 
3p21.1 
Note 
Point mutations observed in 22-25% of MPM; 
additional ~40% may show deletions of one or more 
exons. 
CDKN2A 
Location 
9p21.3 
Note 
Locus consists of overlapping genes encoding tumor 
suppressors p16(INK4) and p14(ARF), both of 
which are usually inactivated in MPM due to loss of 
shared exon 2 sequences.  Homozygous deletions are 
observed in ~90% of MPM cell lines, and 
heterozygous and homozygous deletions are 
detected by FISH in 75-80% of primary MPMs. 
NF2 
Location 
22q12.2 
Note 
LOH due mostly to monosomy 22 in 60-70% of 
MPMs; point mutations observed in 25-55% of 
MPMs. 
TP53 
Location 
17p13.1 
Note 
Mutated in 15-20% of MPM, often reciprocally with 
p19(ARF) loss. 
SETD2 
Location 
3p21.31 
Note 
Point mutations observed in 8% of MPMs; biallelic 
gene inactivation in up to 27% of MPMs. 
Result of the chromosomal 
anomaly 
Hybrid Gene 
While most MPMs have complex genomic profiles 
consisting of numerous genomic imbalances, two 
peritoneal mesothelioma cases were reported to have 
a t(14;22)(q32;q12) as the sole chromosomal 
aberration (see, by Ioannis Panagopoulos entry 
Mesothelioma: t(14;22)(q32;q12) EWSR1/ YY1:, 
http://atlasgeneticsoncology.org//Tumors/t1422q32
q12MesotheliomID.html).  More recently, among 25 
mesothelioma patients aged 40 years or less, a subset 
of 4 cases (16%) were found to have EWSR1 / FUS 
- ATF1 fusions, including 2 patients with MPM and 
two with peritoneal mesothelioma (Desmeules et al., 
2017).  The fusion-positive cases displayed classic 
epithelioid morphology, immunoreactivity for 
cytokeratins and WT1, and negativity for S100.  
BAP1 expression was retained in the 3 fusion-
positive cases with available material.  Overall, 
features of this unique mesothelioma subset include 
young age at presentation, lack of asbestos exposure, 
and retained BAP1 expression. 
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